Matinas BioPharma Reports Third Quarter 2020 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
Matinas BioPharma (MTNB) Reports In-Line Q3 EPS
November 6, 2020 7:11 AM ESTMatinas BioPharma (NYSE: MTNB) reported Q3 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $95.83 thousand versus the consensus estimate of $20 thousand.\The third quarter was very productive for the Company, as we continued to execute on our strategic priorities. We achieved a... More
